e-learning
resources
ERJ
2007
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis
Paul M., Nielsen A. D., Gafter-Gvili A., Tacconelli E., Andreassen S., Almanasreh N., Goldberg E., Cauda R., Frank U., Leibovici L., on behalf of the ...
Source:
Eur Respir J 2007; 30: 525-531
Journal Issue:
September
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Paul M., Nielsen A. D., Gafter-Gvili A., Tacconelli E., Andreassen S., Almanasreh N., Goldberg E., Cauda R., Frank U., Leibovici L., on behalf of the .... The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur Respir J 2007; 30: 525-531
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Relevance of correct antibiotic choice in community-acquired pneumonia (CAP)
Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches
Year: 2005
Antibiotic treatment for nosocomial pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211
Year: 2004
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
Combination versus monotherapy for nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 50-55
Year: 2007
Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis
Source: Eur Respir J 2012; 39: 611-618
Year: 2012
Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens
Source: Eur Respir J 2002; 20: 432-439
Year: 2002
Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Should macrolides be given to all patients with community-acquired pneumonia? Pro argument
Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Year: 2017
The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia
Source: Eur Respir J 2004; 24 : 644-648
Year: 2004
Use of respiratory fluoroquinolones gatifloxacin for treatment of severe community-acquired pneumonia (SCAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 166s
Year: 2006
Fluoroquinolone
versus
β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP)
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Cost-effective antibiotic management of community acquired pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198
Year: 2004
New antibiotics for VAP
Source: Eur Respir Mon 2011; 53: 48-53
Year: 2011
VAP: approach to therapy
Source: Eur Respir Mon 2011; 53: 36-47
Year: 2011
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011
Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 45-49
Year: 2007
Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis
Source: Eur Respir J 2008; 31: 1068-1076
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept